

Hitoshi Kiyoi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/661673/publications.pdf>

Version: 2024-02-01

82
papers

4,482
citations

126907

33
h-index

106344

65
g-index

82
all docs

82
docs citations

82
times ranked

5981
citing authors

#	ARTICLE	IF	CITATIONS
1	Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. <i>Oncogene</i> , 2000, 19, 624-631.	5.9	505
2	Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. <i>Oncogene</i> , 2002, 21, 2555-2563.	5.9	257
3	Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. <i>Blood</i> , 2005, 106, 2854-2861.	1.4	247
4	Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. <i>Blood</i> , 2004, 103, 1901-1908.	1.4	232
5	Target Antigen Density Governs the Efficacy of Anti-CD20-CD28-CD3 Chimeric Antigen Receptor-Modified Effector CD8+ T Cells. <i>Journal of Immunology</i> , 2015, 194, 911-920.	0.8	228
6	Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. <i>Blood</i> , 2011, 117, 2358-2365.	1.4	218
7	Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. <i>Blood</i> , 2009, 113, 4885-4893.	1.4	217
8	Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. <i>Nature Genetics</i> , 2016, 48, 569-574.	21.4	198
9	Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E11711-E11720.	7.1	192
10	A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. <i>Blood</i> , 2011, 117, 2366-2372.	1.4	155
11	A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration. <i>Cancer Immunology Research</i> , 2016, 4, 658-668.	3.4	135
12	FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. <i>Cancer Science</i> , 2020, 111, 312-322.	3.9	124
13	KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. <i>Blood</i> , 2009, 114, 1607-1617.	1.4	108
14	A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations. <i>Blood</i> , 2018, 131, 426-438.	1.4	104
15	Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. <i>British Journal of Haematology</i> , 1999, 104, 659-664.	2.5	101
16	Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia. <i>Blood</i> , 2003, 102, 2969-2975.	1.4	80
17	FLT3 in Human Hematologic Malignancies. <i>Leukemia and Lymphoma</i> , 2002, 43, 1541-1547.	1.3	64
18	Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFβ-MYH11. <i>Blood Advances</i> , 2020, 4, 66-75.	5.2	63

#	ARTICLE	IF	CITATIONS
19	Clinical Significance of FLT3 in Leukemia. International Journal of Hematology, 2005, 82, 85-92.	1.6	61
20	Biology, Clinical Relevance, and Molecularly Targeted Therapy in Acute Leukemia with FLT3 Mutation. International Journal of Hematology, 2006, 83, 301-308.	1.6	60
21	Gene mutations of acute myeloid leukemia in the genome era. International Journal of Hematology, 2013, 97, 165-174.	1.6	56
22	Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2020, 21, 593-602.	10.7	55
23	Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: A report from the BINGO study. Cancer Science, 2010, 101, 2186-2192.	3.9	49
24	Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma. Blood, 2021, 137, 1491-1502.	1.4	49
25	Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. Leukemia Research, 2018, 66, 20-27.	0.8	44
26	Rapid Screening of Leukemia Fusion Transcripts in Acute Leukemia by Real-time PCR. Leukemia and Lymphoma, 2002, 43, 2291-2299.	1.3	43
27	Epigenetic Regulation of CD20 Protein Expression in a Novel B-Cell Lymphoma Cell Line, RRBL1, Established from a Patient Treated Repeatedly with Rituximab-Containing Chemotherapy. International Journal of Hematology, 2007, 86, 49-57.	1.6	43
28	Comprehensive analysis of cooperative gene mutations between class I and class II in <i>de novo</i> acute myeloid leukemia. European Journal of Haematology, 2009, 83, 90-98.	2.2	41
29	Pyruvate secreted from patient-derived cancer-associated fibroblasts supports survival of primary lymphoma cells. Cancer Science, 2019, 110, 269-278.	3.9	41
30	Clonal Analysis of Multiple Point Mutations in the N-ras Gene in Patients with Acute Myeloid Leukemia. Japanese Journal of Cancer Research, 1993, 84, 379-387.	1.7	38
31	FLT3 INHIBITORS: RECENT ADVANCES AND PROBLEMS FOR CLINICAL APPLICATION. Nagoya Journal of Medical Science, 2015, 77, 7-17.	0.3	37
32	Analysis of the joining sequences of the t(15;17) translocation in human acute promyelocytic leukemia: Sequence non-specific recombination between the pml and rara genes within identical short stretches. Genes Chromosomes and Cancer, 1995, 12, 37-44.	2.8	35
33	FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy. Cancer Chemotherapy and Pharmacology, 2001, 48, S27-S30.	2.3	34
34	Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells. Oncotarget, 2016, 7, 47018-47032.	1.8	34
35	A Novel FLT3 Inhibitor FI-700 Selectively Suppresses the Growth of Leukemia Cells with FLT3 Mutations. Clinical Cancer Research, 2007, 13, 4575-4582.	7.0	32
36	Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of <i>CDX2</i> and <i>IDH1/2</i> mutations. Blood, 2022, 139, 1850-1862.	1.4	28

#	ARTICLE	IF	CITATIONS
37	Using peripheral blood circulating DNAs to detect CpG global methylation status and genetic mutations in patients with myelodysplastic syndrome. <i>Biochemical and Biophysical Research Communications</i> , 2012, 419, 662-669.	2.1	25
38	Y654 of Î²â€catenin is essential for FLT3/ITDâ€related tyrosine phosphorylation and nuclear localization of Î²â€catenin. <i>European Journal of Haematology</i> , 2012, 88, 314-320.	2.2	25
39	Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome. <i>Leukemia Research</i> , 2017, 63, 90-97.	0.8	24
40	Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells. <i>Scientific Reports</i> , 2015, 5, 13054.	3.3	22
41	<scp>SPIB</scp> is a novel prognostic factor in diffuse large Bâ€cell lymphoma that mediates apoptosis via the <scp>PI</scp>3Kâ€<scp>AKT</scp> pathway. <i>Cancer Science</i> , 2016, 107, 1270-1280.	3.9	22
42	Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma. <i>Oncogene</i> , 2021, 40, 3989-4003.	5.9	22
43	Peripheral blood cellâ€free <scp>DNA</scp> is an alternative tumor <scp>DNA</scp> source reflecting disease status in myelodysplastic syndromes. <i>Cancer Science</i> , 2016, 107, 1329-1337.	3.9	20
44	Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSC AML201 study. <i>Annals of Hematology</i> , 2019, 98, 83-91.	1.8	19
45	Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia. <i>Cancer Science</i> , 2020, 111, 1314-1323.	3.9	19
46	CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737. <i>Experimental Hematology</i> , 2012, 40, 724-737.e2.	0.4	18
47	Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival. <i>Molecular Therapy</i> , 2021, 29, 2677-2690.	8.2	17
48	FLT3/â€ITD regulates leukaemia cell adhesion through Î±4Î²1 integrin and Pyk2 signalling. <i>European Journal of Haematology</i> , 2011, 86, 191-198.	2.2	16
49	Emetine elicits apoptosis of intractable B-cell lymphoma cells with <i>MYC</i> rearrangement through inhibition of glycolytic metabolism. <i>Oncotarget</i> , 2017, 8, 13085-13098.	1.8	16
50	Donor cell leukemia after allogeneic peripheral blood stem cell transplantation: a case report and literature review. <i>International Journal of Hematology</i> , 2008, 88, 111-115.	1.6	14
51	Introduction of Genetically Modified CD3Î³ Improves Proliferation and Persistence of Antigen-Specific CTLs. <i>Cancer Immunology Research</i> , 2018, 6, 733-744.	3.4	14
52	Current progress and future perspectives of research on intravascular large Bâ€cell lymphoma. <i>Cancer Science</i> , 2021, 112, 3953-3961.	3.9	14
53	GATA2 zinc finger 2 mutation found in acute myeloid leukemia impairs myeloid differentiation. <i>Leukemia Research Reports</i> , 2013, 2, 21-25.	0.4	13
54	<l>FLT3</l> Mutations in Acute Myeloid Leukemia. , 2006, 125, 189-198.		12

#	ARTICLE	IF	CITATIONS
55	A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis. <i>International Journal of Hematology</i> , 2011, 93, 237-242.	1.6	12
56	JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-1. Acute myeloid leukemia (AML). <i>International Journal of Hematology</i> , 2020, 111, 595-613.	1.6	12
57	Minimal residual disease status in pre-B acute lymphoblastic leukemia patients after chemotherapy and bone marrow transplantation: Assessment of the anti-leukemic effects of chemotherapy and BMT. <i>Leukemia Research</i> , 1993, 17, 677-684.	0.8	11
58	Mutation analysis of therapy-related myeloid neoplasms. <i>Cancer Genetics</i> , 2018, 222-223, 38-45.	0.4	11
59	Clinical utility of target capture-based panel sequencing in hematological malignancies: A multicenter feasibility study. <i>Cancer Science</i> , 2020, 111, 3367-3378.	3.9	11
60	Comparison of clonal architecture between primary and immunodeficient mouse-engrafted acute myeloid leukemia cells. <i>Nature Communications</i> , 2022, 13, 1624.	12.8	11
61	Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5472-5477.	2.2	10
62	Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia. <i>International Journal of Hematology</i> , 2010, 92, 624-633.	1.6	8
63	Prevalence and clinical characteristics of N-terminally truncated WT1 expression in acute myeloid leukemia. <i>Leukemia Research</i> , 2011, 35, 685-688.	0.8	8
64	Establishment of a Stroma-Dependent Human Acute Myelomonocytic Leukemia Cell Line, NAMO-2, with FLT3 Tandem Duplication. <i>International Journal of Hematology</i> , 2006, 84, 328-336.	1.6	6
65	Artificial T Cell Adaptor Molecule-Transduced TCR-T Cells Demonstrated Improved Proliferation Only When Transduced in a Higher Intensity. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 613-622.	4.4	6
66	Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 311-318.	1.1	6
67	Immunoglobulin variable region structure and B-Cell malignancies. <i>International Journal of Hematology</i> , 2001, 73, 47-53.	1.6	5
68	Successful Treatment with Imatinib Mesylate of a CML Patient in Megakaryoblastic Crisis with Severe Fibrosis. <i>International Journal of Hematology</i> , 2002, 76, 349-353.	1.6	5
69	Spacer Length Modification Facilitates Discrimination between Normal and Neoplastic Cells and Provides Clinically Relevant CD37 CAR T Cells. <i>Journal of Immunology</i> , 2021, 206, 2862-2874.	0.8	4
70	Prognostic Analysis of Aberrant Somatic Hypermutation of RhoH in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2006, 108, 2041-2041.	1.4	4
71	Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3 internal tandem duplication AML: The JALSG AML209-FLT3-SCT study. <i>Cancer Science</i> , 2020, 111, 2472-2481.	3.9	3
72	Bursitis, Bacteremia, and Disseminated Infection of <i>Mycobacteroides</i> (<i>Mycobacterium</i>) <i>abscessus</i> subsp. <i>massiliense</i> . <i>Internal Medicine</i> , 2021, 60, 3041-3045.	0.7	3

#	ARTICLE	IF	CITATIONS
73	Downregulation of HLA class II is associated with relapse after allogeneic stem cell transplantation and alters recognition by antigen-specific T cells. International Journal of Hematology, 2022, 115, 371.	1.6	2
74	Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy. International Journal of Hematology, 2022, 116, 89-101.	1.6	2
75	Treatment with mTOR Inhibitor, Everolimus (RAD001) Overcomes Resistance to Imatinib in Ph-Leukemia Quiescent or T315I-Mutated Cells.. Blood, 2009, 114, 3277-3277.	1.4	1
76	Clinical Features and Outcomes of Elderly Patients with Acute Promyelocytic Leukemia (APL) - the Japan Adult Leukemia Study Group APL97 Study.. Blood, 2010, 116, 1077-1077.	1.4	1
77	Guest editorial: efficacy of and resistance to molecularly targeted therapy for myeloid malignancies. International Journal of Hematology, 2013, 97, 681-682.	1.6	0
78	Treatment with Hsp90 Inhibitor, 17-AAG Overcomes Resistance to Small Molecule FLT3-Inhibitors in FLT3/ITD-Positive Leukemia Cells Harboring N676K-Mutation.. Blood, 2008, 112, 1619-1619.	1.4	0
79	Biomarkers In Cell Death of Imatinib-Resistant Ph-Leukemia Cells During Treatment with mTOR Inhibitor, Everolimus. Blood, 2010, 116, 3988-3988.	1.4	0
80	Treatment with mTOR Inhibitor, Everolimus (RAD001) Overcomes Resistance to Imatinib In Ph-Leukemia Quiescent Cells.. Blood, 2010, 116, 1579-1579.	1.4	0
81	Rapid Reduction of Chronic Myeloid Leukemia Stem Cells After Treatment with Second-Generation BCR-ABL Kinase Inhibitors, Dasatinib and Nilotinib. Blood, 2010, 116, 4457-4457.	1.4	0
82	FLT3 Inhibitors. , 2017, , 167-179.		0